Skip to main content

Table 2 Anti-TNF treatment history

From: Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study

  UC (n = 35) CD (n = 252)
First-line anti-TNF therapy, n (%)
Infliximab 35 (100) 252 (100)
Treatment period, months, median (IQR) 5.8 (1.4, 8.8) 12.8 (7.6, 33.9)
Second anti-TNF therapy, n (%) 1 (2.9) 10 (4.0)
 Adalimumab, n/N (%) 1/1 (100) 1/10 (10)
 Treatment period, months, median 3.9 (3.9, 3.9) 5.0 (5.0, 5.0)
(IQR)   
 Infliximab, n/N (%) 0 9/10 (90)
 Treatment period, months, median (IQR) 11.2 (7.1, 17.6)
  1. CD Crohn’s disease, IQR interquartile range, TNF tumor necrosis factor, UC ulcerative colitis